Pertussis Completed Phase 2 Trials for Bordetella pertussis filamentous hemagglutinin antigen (formaldehyde inactivated) (DB10788)

Also known as: Whooping cough due to Bordetella pertussis / Whooping Cough / Whooping cough due to bordetella pertussis (B. pertussis)

DBCOND0014696 (Pertussis)Completed2 IdentifierTitlePurposeDrugs
NCT01171989Immunogenicity and Safety Study of GlaxoSmithKline Biologicals' GSK2202083A Vaccine Administered as a Booster DosePrevention
NCT00970307Immunogenicity and Safety Study of GSK Biologicals' GSK2202083A Vaccine in Healthy Infants at 2, 3 and 4 Months of AgePrevention
NCT02301702Maternal Tdap Immunization in GuatemalaPrevention
NCT00355121Study of Menactra® in Children Aged 4 to 6 Years When Administered Concomitantly With a Fifth Dose of DAPTACEL®Prevention
NCT01457495Immunogenicity and Safety of DTPa-HBV-IPV/Hib Compared to DTPa-IPV/Hib and HBV Administered ConcomitantlyPrevention
NCT00362427Study of PR5I, a Pediatric Combination Vaccine With Enhanced Hepatitis B Component Given Concomitantly With Prevnar®Prevention
NCT00376779Immunogenicity and Safety of a DTPa-HBV-IPV/Hib Vaccine Given at 2, 3 and 4 Months of AgePrevention